The impact of psoriasis on health care costs and patient work loss

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

“…In 2008, the U.S. total direct medical costs and indirect costs (i.e., lost productivity) of psoriasis were estimated at $11.25 billion annually, with lost time at work accounting for 40% of the economic burden. 8 People with psoriasis have significantly higher health care resource utilization and costs than the general population. 9 Additionally, the comorbid conditions in patients with psoriasis represent a substantial economic burden to society.…”

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis

“…8 Total direct and indirect health care costs of psoriasis are calculated at $11.25 billion annually in the United States. 9 Loss of work accounts for 40% of the cost burden. 9 Biologics are therapeutic agents derived from human or animal sources or manufactured using recombinant deoxyribonucleic acid (DNA) technology.…”

“…9 Loss of work accounts for 40% of the cost burden. 9 Biologics are therapeutic agents derived from human or animal sources or manufactured using recombinant deoxyribonucleic acid (DNA) technology. Biologics may be proteins, monoclonal antibodies, recombinant receptors, or complex sugars.…”

Current evidence on the effectiveness of systemic herbal medicine for psoriasis: A systematic review with meta-analysis

“…Prevalence is higher in European 1.5%-3.5% [5,6] compared with 0.1%-0.3% in the Far East and China [6,7]. Psoriasis impacts on daily living activities and may cause a financial burden on affected individuals [8][9][10][11][12]. A population-based survey conducted by Stern et al [13] showed that 60% (n=4.5million) of patients report the disease affects their everyday life and 26% (n=4.5 million) report a change or discontinuation of their daily activities.…”